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Complement is an effector system able to mediate a 
number of biological activities in vitro and in vivo. Most 
familiar is the ability of the system to mediate the lytic 
destruction of numerous kinds of cells and pathogenic 
organisms including bacteria, viruses, and virus-in-
fected cells. In addition, the complement system also 
activates neutrophils, monocytes, basophils, mast cells, 
and lymphocytes to perform specialized functions. While 
generally considered to be confined to the effector side 
of immune reactions, recent evidence indicates that the 
complement system also directly recognizes and is trig-
gered by a number of bacteria and viruses as well as 
virus-infected cells in the absence of antibody. In such 
reactions, complement fulfills the recognition role nor-
mally associated with the antibody molecule or immune 
lymphocyte. The complement system may thus also func-
tion as a natural surveillance system operative prior to 
the induction of specific immunity. 
Involvement of the complement system in biological 
reactions has been ascertained by several techniques 
over the years. These include quantitation of individual 
complement components in human sera and demonstra-
tion of complement deposition in diseased tissues in hu-
man diseases and in experimental diseases in animals. 
Such techniques, however, have limitations in specific-
ity and sensitivity. Assays which detect specific features 
of the complement activation process have become avail-
able in recent years. These tests detect the physical, 
chemical, or antigenic changes characteristic of the com-
plement activation process. These assays are extremely 
specific and quantitative; furthermore, most are usable 
with samples from patients. Three general approaches 
have been utilized to develop such specific quantitative 
assays for complement activation. The first includes 
assays which quantitate activation-specific limited pro-
teolysis of the complement components. The second type 
of assay includes tests which detect and quantitate new 
antigens or other activation-specific antigenic changes. 
The third category is represented by assays which detect 
and quantitate the protein-protein complexes character-
istic of the activation process. Examples of tests pre-
senting each of these approaches are given. 
Data from the above approaches together with studies 
of in vitro participation and functions of complement 
molecules in selected reactions such as opsonization 
phagocytosis, chemotaxis, smooth muscle contraction' 
mediator release, etc., indicate that the two most impor~ 
tant biological functions of complement are first the 
production of an acute inflammatory response and sec-
ond, the destruction of infectious agents. Acute inflam-
matory responses serve to confine infective processes 
and thus dissemination. The second major in vivo func-
tion pertains to the role of the complement system in the 
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c~mt~ol of infection_. The complement system directly 
aids In the destructiOn of bacteria, viruses, and virus-
infected cells by several mechanisms, and facilitates 
interactions with effector cells leading to either phago-
cytosis or extracellular destruction of pathogens. These 
processes and their interrelationships are described. 
The primary functions of the immune system include the 
destruction, neutralization, and elimination of pathogenic 
agents and altered host cells. Viruses and bacteria represen t 
the majority of human pathogenic agents. As replicat ing agents, 
they have the ability to serve as a persistent or increasing 
antigenic challenge, furthermore, through mutatio!1 and other 
devices, they have the ability to elude host defenses. It is likely 
that t hey are largely responsible for driving the immune system 
to ever greater complexity and diversity through evolut ion for 
not only must the immune system recognize changing struc-
tures on bacteria, viruses, and virus-infected cells with a high 
degree of specificity, but it must differentiate these antigens 
from host structures. The immune system is conventionally 
divided into humoral and cellular arms with the humoral cate-
gory including the actions of antibody and complement and the 
cellular arm the actions of lymphocytes and various other 
effector cells. These distinctions are artificial as the systems 
are mutually interdependent and function synergistically. 
Complement, the focus of this review, is an effector system 
capable of mediating a number of biological activities in vitro 
and in vivo (Fig 1). Most familiar is the ability of the system 
to mediate the lytic destruction of numerous kinds of patho-
genic organisms including bacteria, viruses, and virus-infected 
cells. Separate from such direct effects, t he complement system 
also triggers or activates various effector cells, including neu-
trophils, monocytes, basophils, mast cells, and lymphocytes to 
perform various functions. Depending on the effector cell in-
volved, complement may trigger the release of secondary me-
diators such as histamine or products of arachidonic acid me-
tabolism, or it may activate intracellular processes, initiate 
directed motion , facilitate phagocytosis, and extrace llular de -
struction of pat hogens as well as modulate immune reactions 
of several kinds. While generally considered to be confined to 
the effector side of immune reactions, recent evidence indicates 
that the complement system also recognizes and is triggered by 
a number of bacteria and viruses as well as virus-infected cells 
in the absence of antibody. In such reactions, complement 
fulfills the recognition role normally associated with the ant i-
body molecule or immune lymphocyte. The complement system 
may thus also function as a natural surveillance system opera-
tive prior to the induction of specific immunity. 
CONSTITUENTS AND REACTION MECHANISMS 
The constituents of t?e complement system, including t he 
vanous regu l_ator protems, are 20 Immunologically distinct 
plasma protems [2-4]. These proteins together comprise ap-
pro~Imately 1_5% (w/ w) of the globulin fraction of plasma as 
the ir cumulat1ve concentration exceeds 300 mg/dl. The com-
plement proteins circulate as individual enti t ies but fo llowino-
activation, which is a prerequisite for t he manifestation of all 
?f ~h_e functional activities of the complemen t system, the 
mdJvidual factors or components undergo a series of precisely 
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regu lated interactions with the activating substance and with 
each other. Activation is not a single event, but rather a 
dynamic conti nuing process which enables t he proteins of the 
system to become interacting members of a functionally inte-
grated system. 
The reactions of the complement components and factors 
wit h the activator and with each other can be grouped into 
seve ral reaction units, each of which involves severa l comple-
me nt proteins (Fig 1) . There are two ent irely separate act iva-
tion pathways termed the classical [5,6) and the alternative or 
properdin pathways [7,8] respectively. T hese activation path-
ways are independently tr igge red by certain types of agents. 
For the classica l pathway t hese include immune complexes 
containing lgG 1, lgG2 or lgG3, or lgM antibodies. ln addi t ion, 
however, t he classica l pathway may be activated, in the com-
plete absence of antibody, by a number of different kinds of 
substances, a ll of wh ich have pathobiological potential in hu-
mans. These include seve ra l kinds of bacteria, viruses, and 
virus-infected ce ll s, lipid A and rough lipopolysaccharide mol-
ecules, membranes of trans formed and altered cells, lysosomal 
enzymes, and a number of other substances of diverse chemical 
and physical composition [9- 11] . 
During the activation process, t he fi rst component of t he 
classical pathway, termed Cl, is converted from its native form 
into a proteolytic enzyme wh ich activates t he next two reacting 
complement components, C4 and C2, by limited proteolysis 
[5,6,9, 10] (Fig 1 ). The larger cleavage fragments of each of t hese 
molecu les have t he ab ili ty to bind to each other and form a 
C4,2 protein -protein complex. The C4,2 complex represents 
another de novo- formed complement enzyme which has the 
ability to proteolyze C3, the next reacting factor. With the 
cleavage of C3, again by hyd rolysis of a single peptide bond, 
yet another enzyme is formed which has the ability to cleave 
and act ivate C5 and thereby to initiate t he terminal portion of 
the complement reac tion sequence (Fig 1). The classical path-
way thus consists of a series of enzyme-substrate reactions in 
which facto rs are activated by limited proteolysis. The larger 
cleavage fragments inte ract with each other thereby form ing 
prote in -protein complexes which have de novo enzymatic ac-
tivity directed at the next reacting complement factor. During 
classical pathway activation, C1 binds to the activator whether 
it be an immune complex, bacterium, virus, virus- infected cell 
or other activato r. Although a relatively minor proportion of 
the larger cleavage fragme nt of C4, C2 and C3 bind to t he 
surface of the activator, and to each other, assembly of t he 
complement enzy mes on activator surfaces is far more efficient 
t han in t he fluid phase. Reactions on the activator surface also 
obviously foc us the actions of t he complement system on the 
activator. While the smaller cleavage products do not gene rally 
bind to the surface of t he activator and are released into the 
11uid phase, some of these fragments have important biological 
activities, as wi ll be considered subsequently. 
The alternative complement pathway is usually activated 
directly, in the absence of ant ibody [7 ,8]. Activators include 
complex polysaccharides, particularly those associated with 
bacteria, certain viruses and virus-infected cells and other types 
of altered cells as well as lipopolysaccharide molecules. Specific 
antibody also potentiates a number of alternative pathway 
activation reactions and appears to be, in certain limited in-
stances, also responsible for activation . The alternative path-
way is initiated by t he binding of an altered form of C3 or t he 
larger cleavage product of C3 to the surface of activators (Fig 
1). On such structures, it interacts with Factor B, which after 
complexing is rendered suscept ible to limited proteolys is by 
Factor D, a proteolytic enzyme. The C3,B protein-protein com-
plex containing the larger cleavage products of C3 and Factor 
B represents a de novo proteolytic enzyme able to fragment 
addit ional molecules of C3, aga in by limited proteolysis. The 
attachment of the larger cleavage product of C3 in proximity 
to the C3,B complex fo rms another proteolytic enzyme, C3, ,B 
able to hyd rolyze C5 and ini tiate the membrane attack pathway. 
Thus, and in analogy to the classical pathway, activation in-
volves t he sequent ial fo rmation of protein-protein complexes 
with de novo enzyme activity. 
The membrane attack pathway is initiated following limited 
proteolysis of C5 by the C5 cleaving enzyme of eit her t he 
classical or the alternative complement pathways (Fig 1) [12, 
13]. Following cleavage of C5, the remaining components, C6, 
C7, C8, and C9 inte ract with C5 and with each other to form a 
large multimolecular complex, C5b-9, termed the membrane 
attack complex. This protein-protein complex has the t ransient 
abi li ty to disrupt lipid-containing membranes. It is responsible 
for the cytolytic activity of the activated complement system. 
The activities of t he complement pathways are precisely 
regulated by a number of processes including labi lity of binding 
sites, dissociation of complexes and by the actions of a group 
of proteins, enzymes, and functional site inhibitors. Wit h re-
gard to the latter, the classical pathway is modulated by t he 
actions of C1- inhibitor, a protein which regulates t he actions 
of activated Cl , and by C4-binding protein, which binds to the 
larger cleavage fragment of C4 and facilitates t he further deg-
radation of this fragment by a complement regulator enzyme 
termed Factor I. The alte rnative pathway is up-regulated by 
the action of properdin , a protein which stabilizes the actions 
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of t he C3,B and C3b,,B enzymes and down-regulated by a 
protein termed Factor H which binds to the large r cleavage 
fragment of C3 and faci li tates its destruction by Factor I. 
Another regulator, S protein, controls and modulates the activ-
ity of t he assembling membrane attack complex. Finally, a 
carboxypeptidase in plasma termed carboxypeptidase N or 
anaphylatoxin inactivator removes the C termina l argin ine 
residues from C3a, C4a, and C5a, t he smaller cleavage frag-
ments of C3, C4, and C5, respectively, t hereby abrogating 
certain of the biological activities of these fragme nts [14]. 
ASSESSMENT OF COMPLEMENT INVOLVEMENT 
Involvement of t he complement system in biological reac-
t ions has been ascertained by a number of techniques over the 
years (2,15- 17]. These include quantitation of individual com-
plement components in human serum either by functional 
assays based on immune hemolysis or by immunochemical 
methods, such as the Mancini and rocket immunodiffusion 
techniques. Reduction in the levels of certain complement 
components in the circulation is st rongly suggestive of in vivo 
complement activation. This is in part because the funct iona l 
activity of many of the complement components is lost with 
activation; furthermore , severa l of the activated, cleaved com-
plement molecules, in particul ar, the large r cleavage products 
of C3, C4, C5, and Factor B, are rapidly cleared from t he 
circulation. The most useful measurements, regardless of the 
method used, a re of C2, C3, C4, C5, and Factor B. Selective 
activation of either the classical or a lternative pathways may 
be ascertained if multiple components a re measured since a 
reduction in the levels of C2, C3, and C4 in the circulation 
without marked changes in t he concentration of Factor B 
strongly suggests classical pathway activation while a reduction 
in Factor B and C3 levels with minor changes in the classical 
pathway component levels is characteristic of alternative path-
way activation. Predominant activation of the classical path-
way characterizes several infectious diseases and autoimmune 
diseases, particularly those involving immune complexes. Al-
ternative pathway activation is found in membrana-prolifera-
tive glomerulonephri tis, certa in in fectious diseases, and in 
shock accompany ing burns , traumatic injury, and infection 
with gram negative bacteria. 
A major limitation of measurements of the circulating levels 
of complement components as a technique for assessing com-
plement activation is that on ly very marked activation can be 
detected by these techniques. This is because the complement 
factors are normally synthesized and metabolized at approx i-
mately 2% of the plasma pool per h, an extraordinarily rap id 
rate. Within this normal background of rapid synthesis and 
degradation, increased utilization is difficult to detect. 
Complement involvement has also been frequently demon-
strated by showing deposition of complement components, 
generally C1q, C3, and C4 and sometimes properdin, Factor B, 
or C5b-9, often together with immunoglobulin, in areas of t issue 
damage in human diseases and in experimental diseases in 
an imals. Most often, ·the bound complement components are 
demonstrated by immunofluorescence techn iques. While t he 
findi ng of complement components in tissues, particularly in 
association wit h a pathogen or immunoglobulins constitutes 
excellent evidence for complement involvement, t he extent of 
activation cannot be quantitated, and tempora l correlations a re 
not possible since complement components can remain in tis-
sues for prolonged periods of time. 
A number of assays which detect specific features of the 
complement activation process have become avai lable in recent 
years [ 15]. These tests detect t he physical, chemical, or anti-
genic changes which occur in the complement components with 
the activation process. Assays designed to detect and/or quan-
titate such activation -dependent changes are extremely spec ific 
and most allow quantitation of activation; furthermore, many 
TABLE I. Complement activation assays detecting specific features of 
the complement activation process 
Measurement of co mplemen t compo nent cleavage a nd/o r cleavage 
products 
C l activation assay 
Demonstration of C3, C4, C5, or Factor B cleavage by electrop horetic 
tec hniques 
Immunoelectrophores is 
Counter immunoelectrophoresis 
Crossed immunoelectrop hores is 
Quantitation of C4d/C4 
Selective precipitation/quanti tation 
C4d/C4 rocket electrophores is 
Quantit.ation of C3a, C4a, a nd C5a by radioimmunoassay 
Assays for complement. activation detecting a lte rations in a ntigenicity 
Demonstratio n of neoantigens 
Determ ination of the Cl r:Cl s antigenic ratio 
Functiona l immunoassay for Cl- inhibi to r 
Assays for activation-dependent protein-protein complexes 
Quantitation of C lrCls-Cl- ln complexes 
Crossed immunoelectrophoresis 
Rocket im munoelectrophoresis 
IN CA (C I-inhibi to r co mplex assay) 
Class ical pathway ELISA 
Alternative pathway EL ISA 
of the tests are · applicable to use with samples of blood or 
tissues from patients. 
The t hree general approaches which have been used are 
depicted in Table I. The first includes assays which detect the 
limited proteolysis of certain of the complement components 
characteristic of the activation process. The second approach 
includes assays which detect and quantitate either new antigens 
or other antigenic changes appearing as a result of activation. 
The third approach is represented by tests which detect and 
quantitate the protein-protein complexes which occur during 
the activation process. 
An example of an assay which detects cleavage of a comple-
ment component during activation is depicted in Fig 2. With 
activation of the classical pathway, t he C1r and C1s subunits 
of Cl undergo limited proteolysis. This is shown in Fig 2, which 
depicts t hese changes in Cls, as seen in a sodium dodecyl 
sulfate-polyacrylamide gel electrophoretic analysis [15,18]. 
During C1 activation, the 87,000 dalton polypeptide chain of 
native C1s is cleaved at a single residue yielding 59,000 and 
28,000 dalton fragments. Cleavage can be readily assessed by 
t racking radioactivity. Similar studies can be carried out with 
a number of the other complement components which undergo 
limited proteolysis during the activation process. Several other 
approaches which detect specific activation-dependent cleavage 
of the complement components during the activation process 
are shown in Table I. Notable among these are the very sensi-
tive, recently developed radioimmunoassays which detect and 
quantitate the smaller C3a, C4a, and C5a fragments in C3, C4 
and C5 respectively (14,19-21]. These radioimmunoassays, 
which are now commercially available, detect less than 20 ng/ 
ml of the activated products in human plasma or sera. They 
are thus far more sensitive than other approac hes to measure 
C3, C4, and C5 cleavage. Furthermore, t hey are quantitative. 
Such assays furnish some of the best of the newer quantitative 
techniques to assess complement activation by measuring spe-
cific features occurring during t he activation of the complement 
system. 
The second type of assay system detects activation-induced 
changes in the antigenic structure of t he complement compo-
nents (Table 1) . In some cases new antigens not present in the 
native molecules are produced during activation. Antibodies 
formed against t hese neoantigens do not react with native 
molecules. Neoantigens are known to appear with activation of 
C1q, C3, Factor B, and the C5-C9 membrane attack complex; 
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it is likely t hat more such antigens will be described with 
additional applications of t he monoclonal ant ibody technology 
to t he study of complement activation. An assay of t his type 
which has been employed is the Clr-Cls antigenic ratio [22). 
With activation of t he complement system in serum, C1 r an-
tigenicity disappears. T his dramatic change is due to masking 
of many of t he major antige ns of activated C1r by the control 
protein Cl- inhibitor which rapidly binds to activated Cl r [23). 
This disappearance of Clr antigenicity with activation has been 
utili zed to demonstrate activation in patient samples [22-24]. 
A related approach has been employed to determine the func-
tional levels of Cl inhibitor in human serum or plasma and has 
been proposed as a diagnostic test for Cl-inhibi tor functional 
defici ency as associated with certain kinds of angioedema 
i.e., heredita ry a ngioedema (HAE) [25]. In t hi s assay, shown in 
Fig 3, a known complement activator such as aggregated im-
munoglobul in is incubated with normal serum as well as with 
t he test serum suspected of having reduced levels of Cl- inhib-
itor. C1 r is subsequently assayed by radial immunodiffusion. 
In norma l serum, C1r antigenicity disappears fo llowing acti-
vation of the complement system, whereas in serum lack ing 
funct ional Cl- inhibitor, t here is no reduction in the apparent 
Clr concentration (Fig 3) . 
T he t hird type of approach which detects specific features of 
t he complement activation process utilizes assays which quan-
titate the protein-p rotein complexes characteristic of t he com-
plement activation process (Table 1). Since such protein-pro-
tein complexes a re not present in native serum or plasma but 
only occur following activation , such assay systems have very 
high spec ificity and low background or nonspecific reactivity. 
Fig 4 depicts enzyme-linked immunosorbent assays which de-
tect protein-protein complexes characteristic of activation of 
both t he classica l and the alternative complement pathways 
[15,25,27]. T he classical pathway ELISA detects t he complex 
of Cl -inhibito r with activated Cl r and Cl s, subunits of Cl. Cl-
inhibitor rapidly and irreversibly combines with activated Clr 
and Cls; it does not interact with t he native forms of t hese 
molecules and thus the complex is not found in normal serum. 
The assay is able to detect activation of less t han 1% of t he 
classical pathway in human plasma [15,27]. In t he assay, anti-
body to C1s is attached to the plastic microliter well , t he 
mixture containing activated Cl or a sample from patients 
potentially containing activated Cl is then added to t he wells. 
Next, enzyme- labeled antibody to C1-inhibitor and finally sub-
strate is added. Color development is proportional to t he con-
centration of the ClrC1s-C1 -In complex. P rec ise quantitation 
can be a fforded by simul taneous inclusion of standards. 
The alte rnative pathway ELISA, shown in Fig 4, detects a 
complex formed between properdin and C3b [15,26]. This com-
plex is diagnostic of alternative pathway activation. In t he test 
~ ~ ~ 
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FIG 2. Assessment of Cls cleavage 
during Cl activation by sodium dodecyl 
sulfate-polyacrylamide gel electrophore-
sis. Reprinted from [1 5] with permission. 
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F IG 3. Immunodiffusion assay to assess Cl -ln function. A normal 
(BM) and an HAE (ST) se rum were incubated in the presence or 
absence of 2 mg/ ml agg lgG at 37"C for 60 min. The patte rns obtained 
on analyzing the samples in duplicate for Clr by single radial immu-
nodiffusion are shown. The disappearance of the precipitin ring in 
NHS after treatment with agg lgG and the unaffected pattern obtained 
with the HAE serum allows visual identification of the HAE serum. 
Reprinted from [25] with permission. 
system, ant ibody to properdin is coupled to t he plastic plate, a 
sample or serum from patients or an activator mixture is added 
and C3,B complexes are detected with enzyme-labeled antibody 
to C3. This assay is extremely sensitive and able to quantitate 
activation of approximately 10 ng/ml of C3 which, in human 
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ALTERNATIVE PATHWAY ELISA CLASSICAL PATHWAY ELISA 
Enzyme 
labeled 
~~aCl - ln FIG 4. Classical pathway a nd a lter-
native pathway ELISAs. Reprinted from 
115] wit h permision. 
Activator-serum mixtures are placed in anti-properdin 
coated wells and reacted with enzyme labeled anti-C3 
Activator-serum mixtures are placed in anti·C 1 s coated 
wells and reacted with enzyme labeled anti-C ! ·inhibitor 
plasma, corresponds to activation of only 0.015% of the C3 in 
plasma. 
BIOLOGICAL FUNCTIONS OF COMPLEMENT IN 
VIVO 
Information on the biological importance of the complement 
system has come from two main sources. These are demonstra-
tions of complement involvement by direct measurement or 
detection in damaged t issues in human diseases and in experi-
mentally- induced diseases in animals employing t he kinds of 
techniques listed above and in Table L The second source of 
information has been the study of humans who are congenitally 
deficient in complement proteins or in complement regulators. 
As indicated in Table II, such individuals exhibit 1 of 4 types 
of disease. Genetic absence of components of the classical 
pathway including the C1 subcomponents, as well as C4 and 
C2, is frequent ly associated with autoimmune-type diseases 
including systemic lupus erythematosus, glomerulonephri t is, 
and occasionally repeated infections. More than half of the 80 
or so reported individuals with t hese deficiencies a re clinically 
ill and suffer from one of these diseases. In cont rast, individuals 
lacking C3 or its regulator protein , Factor I, suffer from recur-
rent life-threatening infect ions wi th pyogenic organisms. The 
third disease complex characterizes defi ciencies of the late 
reacting complement components, C5, C6, C7, and C8. Recur-
rent life-threatening systemic infections with go nococci or 
meningococc i occur in more than half of t he individuals with 
these sympto ms; systemic infection with N eisseria is frequently 
the presenting symptom of patients with such deficiencies. 
Patients having congeni tal deficiencies of C1 inhibitor have 
heredita ry angioedema. Individuals lacking this crucial control 
protein have uncontrolled activation of the classical comple-
ment pathway and also exhibi t in vivo activation of t he other 
effector systems regulated by the inhibi tor. 
Data fro m the above approaches as well as studies of in vitro 
participation and functions of complemen t molecules in se-
lected reactions such as opsonization, phagocytosis, chemo-
taxis, smooth muscle contraction , mediator release, etc., indi -
cate that the two most important biological funct ions of com-
plement are the production of an acute inflammatory response 
and t he destruction of pathogens including bacteria, viruses, 
and virus infected cells (Table Ill ). The complement system 
has the ability to produce an acute inf1ammatory response (Fig 
1). The inflammatory response is primarily produced by C3a, 
C4a, and C5a. These hormone- li ke peptides enhance vascular 
permeability, release mediators such as histam ine from mast 
cells and basophils, induce smooth muscle cont raction, and 
trigger lysosomal enzyme release from granulocytes. In addi-
t ion, C5a releases leukotrienes from pulmonary tissue (13,27]. 
Furthermore, C5a a lso is chemotactic and able to initiate the 
directed migration of leukocytes into an area of complement 
TABLE II. Inherited complement deficiencies 
Component lacking 
C lr, Cls, C2, C4 
C3, Factor I 
C5,C6,C7,C8 
C l inhibi to r 
Disease association 
Systemic lupus erythematosus and 
systemic lupus erythemawsus-
like syndrome, dermatomyositis, 
glomerulonephri tis 
Recurrent pyogenic infection 
(p neumococcus, staphy lococcus, 
streptococcus) 
N eisseria infections 
Hereditary angioedema (HAE) 
TABLE III. Biological functions of complement in. vivo 
Acute inflammatory response 
Destruction of pathogens 
Direct- via impairment of infectivity 
Indirect- via phagocytosis a nd re lease of mediators 
activation. This same pept ide also aggregates polymorphonu-
clear leukocytes and induces additional release of intracellular 
enzymes and proteins from these cells. The actions of t he 
anaphylatoxins and the secondary mediators released from the 
cells by t he anaphylatoxins are integrated with each other; 
furthermore, several have similar biological activities and they 
are mutually self-reinforcing (Fig 1). These in vitro biological 
activities are responsible for t he phlogistic activity of the com-
plement system. 
An acute inf1ammatory response serves t he major function 
in vivo, of confi ning an infective process and retarding its 
spread throughout t he body. At t he same t ime as the acute 
inf1ammatory response is occurring, C5a, also having chemo-
tactic properties, is responsible for triggering leukocyte in fi ltra-
tion. Incoming leukocytes become fixed in the area of comple-
ment activation through attachment to specific receptor sites 
located on the larger cleavage products of C3 and C4. Subse-
quent phagocytosis and/or release of other mediators and ly-
sosomal enzymes facilitates t he destruction of the infective 
agent. Other properties of the activated complement system 
including its cytolytic ability also facilitate the cytotoxic de-
struction of pathogens. These va rious properties will be de-
sc ribed below. 
The second major funct ion of the complement system in vivo 
relates to its role in the control of in fect ion. The complement 
system directly aids in the destruction of infectious agents, 
primarily bacteria and viruses by several mechanisms. It a lso 
possesses the ability to destroy virus-infected cells. Comple-
ment faci li tates interactions with effector cells lead ing to either 
phagocytosis or extracellular destruction. 
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COM P LEMENT ACTIVATION BY PAT HOGE NS 
Numerous bacteria l and vira l structures are ant igenic or 
gene rate t he formation of ant ibody. On subsequent exposure to 
t he pathogen such elicited antibody can mediate complement 
activation. In addit ion, however, many bacteria, part icularly 
gram negative bacteria, directly activate complement in the 
absence of ant ibody [11,29,30]; this is a lso t rue of a number of 
viruses and virus- in fected cells [31,32]. Such direct activation, 
which has now been observed for a nu mber of di ffe rent bacte ria l 
and vira l pathogens as well as wit h mycoplasma and parasit ic 
organisms, suggests t hat t he complement system fulfill s a pri-
ma ry surve illance function ent irely analogous to t he actions of 
natural killer cells. 
As noted, some bacteri a activate t he complement system in 
the absence of ant ibody; such activation is augmented by an-
tibody. Certa in kinds of gram negative bacteria may be killed 
by the complement system, in some cases in t he complete 
absence of ant ibody [33], while in most instances ant ibody is 
required for killing [30]. As depicted in Fig 5, bacte ria t reated 
wit h isolated complement components of the a lternative path-
way together with the purified components of the membrane 
attack complex in t he absence of ant ibody are somewhat larger 
and have irregu la ri t ies in surface structure. The killed bacteria, 
although not lysed, also possess numerous complement-de-
pendent lesions characte ristic of the fo rmatio n of t he mem-
brane attack complex on lipid bilayers when examined by 
FI G 5. Scanning electron microscopy of alte rnative pathway t reated 
E. coli Kl2. Shown are E. coli t reated at 37•c fo r 60 min wit h buffe r 
or t he heat-inactivated (56·C, 30 min) isolated component mixture 
(upper left panel ), the isolated component mixtu re (upper right and 
lower left panels), or the isolated component mi xture containi ng 10 p.g/ 
ml egg whi te lysozyme (lower right panel). Concom itant analys is of 
viabili ty a nd lys is revealed t hat compa red to the cont rol (upper left 
panel ), samples (upper right and lower left) were killed but not lysed, 
whereas sample (bottom right) was ki lled and lysed. Reprin ted from 
[33] wit h permission. 
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transfl!i ssion electron microscopy. Bacteria l lysis, which is ac -
complished only on addi tio n of lysozyme, and as depicted in 
Fig 5, leads to complete loss of structure. 
Complement acti_vation by viruses also leads to complemen t 
component depos1t1?n ~n t he extern_a l surface ~ f virus regard-
less_ of whether acttvatwn occurs dtrectly, or 1s mediated by 
ant tbody. In the case of isolated virions, bound compleme t 
c?mponents rna~ reduce infectivi ty by one or more of seve r~! 
d~ stmct mecha_msms whtch have been observed wit h variou s 
vtrus~~- ~he~e mclud~ aggregation which reduces t he net num-
?er o~ mf~ctwus particles; envelopment which refers to a coat-
m_g of ant tb??Y and/or c_omplement protein which may interfe re 
wtt h th~ abtiity of t he v1rus to attach to and infect a potent ia l! 
suscept ible ~ell; ~nd cytolytic destruction which irrevers ib l~ 
destroys mfecttvtty [31,32). Alt hough many viruses may b 
a_ggre_gated in_ vit ro by ant ibody, complement -dependent agglu~ 
tmat10~ leadmg to ~eutra lization has t hus far been observed 
only With polyoma vtrus, a nonenveloped DNA-containin " v i-
rus. Envelopment as a mechanism of neut ralization has bee 
found to be the major process by which ant ibody and/or com~ 
plement neut ralizes most of the viruses t hus fa r examined . 
Alt hough most and probably all enveloped viruses may be lysed 
by complemen~ under appro~riate circumstances, as shown, fo r 
exafl!ple, m Ftg 6, t hose vtruses which hav_e been_ carefully 
studied have been found to be fully neutralized pn or to t h 
occurrence of lysis [31] . e 
Co~pleme_nt ~ctivation by virus in fected cell s, whether direct 
or ant1b_ody -1mt1ated, leads to complement deposition on t h e 
cell surface. Such components may prevent virus maturation 
as has been observed fo r ant ibody. The virus- in fected cell rna; 
also. be lysed by the c?mp_lement system [31,36]. Extensive 
studtes ~ave shown lysts of such cells to be mediated by t he 
alternattve complement pathway in conjunction wi th t he mem-
brane attack pathway [31,32,36,37) . Although activation does 
n ~t require the p~esence of antibody [38], cytolytic destruction 
of t he ~e lls reqUires t he presence of both ant ibody and t he 
properdm system [37,38). Obviously, lysis of t he virus- infected 
cell prevents virus maturation. 
Undoubtedly very important in virus defense is t he ability of 
the complement system to augment Fc-dependent opsonization 
o~ to m~d i ate .~o mplement receptor-dependent interaction~ 
wtth van ous effect?r cells bearing receptors fo r the la rger 
cleavage products of C3 or C4. Numerous cell types including 
lymphocytes, mac rophages, monocytes, and neut rophils bear 
re_ceptors for one or more activated comp lemen~ componen ts; 
ot t hese, receptors for C3 appear to be the most Important. C3 
or C4 fragments which become attac hed to the surface of the 
bacteria, virus, or virus-infected cell as a consequence of ant i-
body-dependent or ant ibody- independent activation of t he 
complement ~~stem may mediate binding of these activators to 
the varwus effecto r cell types bearing C3 or C4 receptors. Such 
attachment may t rigger specialized reactions by the effector 
cell, depending on the target and effector cell as well as the 
comp_lement fragments and receptors involved. Such responses 
~ay m~lud~ chemota_xis, _extracellula; cytotox icity, phagocyto-
SIS, act1vatwn o~ ox1_dat 1ve. metabolism, an? t he respiratory 
burst: mttogenests, stunulatwn of arac hadomc acid dependent 
reactwns as well as a number of other reactions [14,39,40] . 
Bacteria which have reacted wi th antibody and/or the com-
plement system represent an opsonic stimulus for the polymor-
phonuclear leukocyte. An example of phagocytosis of comple-
ment_-coate? bact~ria by neut rophils i ~ depicted in Fig 7 [40). 
In t h1s part icular mstance, phagocytosis, as shown in t he right -
hand panel, is independent of involvement of ant ibody since 
the purified a lternative pathway prote ins at physiologic con-
cent rations in t he absence of antibody were employed for t his 
study. In many other instances, such phagocytosis is antibody 
as well as complement-dependent [30,40). 
Antibody and/or complement components deposited on iso-
lated virions and on virus-infected cells as a consequence of 
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FIG 8. Inges tion of complement coated Epstein-Barr virus by a 
polymorphonuclear leukocyte. Reprinted from [41] with permission. 
c 
SOnm 
FIG 6. Sections of purified lympho-
choriomen ingitis virus (LCMV) exposed 
to (A) normal co ntrol serum , (B) heated 
gui nea pig serum containing a ntibody to 
LCMV, (C- F) guinea pig serum conta in -
ing antibody a nd complement. Ar-rows in 
(F) point to disrupted viral envelope re-
leasing vira l core material. Reprinted 
from [35] with permission. 
FIG 7. Sca nning electron micrograph 
of polymorphonuclear leukocytes 
(PMNL). PMNL were incubated for 5 
min at 37"C with unopsonized E. coli 04 
(A) or with E. coli 04 which had been 
preincubated with the purified alterna-
tive pathway proteins (B) . After wash-
ing, PMNL were fixed with modified 
Karnofsky fixative and prepared for 
electron microscopic a nalysis. Reprinted 
from [40] with permission. 
complement activation can mediate the attachment of the virus 
part icles or in fected cells to lymphocytes and other cell types 
bearing such receptors. Such interactions may lead to extracel-
lular destruct ion of virus- infected cells (36] and potentia lly also 
of isolated viruses, although t he latter has not been convinc-
ingly shown. The bound protein may also be opsonic and trigger 
ingestion. An example is shown in Fig 8 which depicts phago-
cytosis of ant ibody and complement-coated Epstein-Barr virus, 
a human herpesvirus, by polymorphonuclear leukocytes (GR 
Nemerow, NR Cooper, unpublished studies). 
CONCLUSIONS 
This review has briefly summarized t he nature of the com-
plement proteins and their reaction mechanisms and described 
various tests to determine participation of t his system in human 
disease. It has concluded with an assessment of the kinds of 
biological reactions in which complement is likely to play a 
major role in vivo. These include mediation of, and involvement 
in , int1ammatory processes. In infectious diseases, int1am-
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mation serves to restrict t h e spread and dissemination of the 
infection. Inflammation is a lso a prominent feature of a number 
of other diseases which are not infectious in origin. In these 
instances, such as observed in autoimmune diseases, as well as 
in tissue injury due to infarction, trauma, shock, or burns, 
complement may both produce and a lso augment t he inflam-
matory processes which occur. l n a ll of these conditions, com-
plement mediates processes which are destructive to normal 
tissues. The other major category of complement-dependent 
actions has to do with the prevention, contro l, and recovery 
from infection. T he complement system likely finds its major 
importance in vivo in this broad area. 
In addition to these well-characterized actions, other prop-
erties which have been incompletely studied suggest t hat com-
p lement fulfills other physiogenic functions in v ivo. For ex-
a mple, t he reasons for the increased susceptibility of individuals 
genetically lacking in the components of the classical pathway 
to a utoimmune diseases is completely obscure. This increased 
preva lence may be related to an as yet unapprec iated role for 
the complement system in immune recognition, regulation, or 
other related reactions. J n this context, the presence of t he 
struct ural genes for C2, C4, and Factor B, but not other 
complement components within the major hi stocompatibility 
complex in humans, a region involved in self, nonself discrim -
ination, may be important. Anothe r potentially related, and as 
yet not understood role for complement may be in the induction 
of immune responses to certain T-dependent antigens. Anum-
ber of papers have been published which have suggested a role 
for complement in a number of kinds of reactions involving 
various aspects of immune regu lation. It is likely that further 
study will reveal additional biological functions for this highly 
complex, well-differentiated system. 
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